MXCT — MaxCyte, Inc.
Is MXCT overbought or oversold? Here is the current MarketMoodz read.
MaxCyte, Inc. (MXCT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $1.18.
- Public ratingOversold (as of November 17, 2026)
- Last close$1.18
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
MaxCyte, Inc. (MXCT) operates a platform business that benefits from recurring consumable demand and partner collaborations, offering defensive elements relative to single-asset biotechs. Growth prospects are supported by secular demand in cell and gene therapy and an expanding partner base, but the company faces material financing and dilution risks, clinical/regulatory readthrough sensitivity from collaborators, and limited liquidity that can amplify volatility. Near-term performance will likely hinge on cash runway updates, milestone recognition from partners, and broader sentiment toward growth-oriented life-science suppliers.
Key factors
- Platform business model with recurring revenues from instrument sales and consumables supports revenue visibility versus pure-play drug developers
- Broad partner ecosystem and licensing/collaboration agreements provide non-dilutive funding and commercial validation of the electroporation platform
- Sector thematic tailwinds for cell and gene therapy and outsourced bioprocessing could drive steady demand for MaxCyte’s technology
- Market-wide risk-on sentiment and rotation into growth areas could improve sentiment for platform-enabled life-science suppliers in the near term
- Limited public-market disclosure in the provided data increases reliance on historical business model durability and partner strength for valuation
Risks
- Near-term liquidity and cash-burn concerns that could necessitate dilutive financing (convertible debt or equity), pressuring shareholder value
- Concentration risk from dependence on a limited set of large collaborators or milestones for revenue spikes
- Competitive risk as alternative cell-engineering technologies or in-house solutions by larger CDMOs reduce addressable share
- Regulatory or clinical setbacks at partner programs that use MaxCyte’s platform could meaningfully affect partner revenue streams and milestone recognition
- Low public investor attention and thin trading liquidity can amplify price moves and increase volatility
- Macroeconomic or sector-wide risk aversion that reduces capital availability for partners and customers, slowing instrument and consumable purchases
See today's live rating, score and targets
Members see the live hourly rating for MXCT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.